close
References
  1. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S15-S33.
  2. Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020. www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed January 12, 2021.
  3. Rogers MAM, Kim C, Banerjee T, Lee JM. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Medicine. 2017;15(1):199.
  4. Quinn M, Fleischman A, Rosner B, Nigrin DJ, Wolfsdorf JI. Characteristics at diagnosis of type 1 diabetes in children younger than 6 years. J Pediatr. 2006;148(3):366-371.
  5. Muñoz C, Floreen A, Garey C, et al. Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives. Clin Diabetes. 2019;37(3):276-281.
  6. Rewers A, Dong F, Slover RH, Klingensmith GJ, Rewers M. Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998-2012. JAMA. 2015;313(15):1570-1572.
  7. Alonso GT, Coakley A, Pyle L, Manseau K, Thomas S, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010–2017. Diabetes Care. 2020;43(1):117-121.
  8. Hawkes CP, Willi SM. A trend towards an early increase in ketoacidosis at presentation of paediatric type 1 diabetes during the coronavirus-2019 pandemic. Diabet Med. 2021;38(4):e14461.
  9. Dabelea D, Rewers A, Stafford JM, et al; SEARCH for Diabetes in Youth Study Group. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics. 2014;133(4):e938-e945.
  10. Couper JJ, Haller MJ, Greenbaum CJ, et al. ISPAD Clinical Practice Consensus Guidelines 2018: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2018;19(suppl 27):20-27.
  11. Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19(suppl 27):155-177.
  12. Duca LM, Wang B, Rewers M, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care. 2017;40(9):1249-1255.
  13. Usher-Smith JA, Thompson MJ, Sharp SJ, Walter FM. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a systematic review. BMJ. 2011;343:d4092.
  14. Butler AE, Misselbrook D. Distinguishing between type 1 and type 2 diabetes. BMJ. 2020;370:m2998.
  15. Lawrence JM, Slezak JM, Quesenberry C, et al. Incidence and predictors of type 1 diabetes among younger adults aged 20-45 years: the Diabetes in Young Adults (DiYA) study. Diabetes Res Clin Pract. 2021;171:108624.
  16. Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Ther. 2017;8(3):475-487.
  17. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974.
  18. JDRF. T1Detect Frequently Asked Questions. www.jdrf.org/t1d-resources/t1detect. Accessed May 18, 2021.
  19. TrialNet. Pathway to Prevention. Study Details. www.trialnet.org/our-research/risk-screening. Accessed December 20, 2020.
  20. Lorenzen T, Pociot F, Hougaard P, Nerup J. Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia. 1994;37(3):321-327.
  21. Erlich H, Valdes AM, Noble J, et al; Type 1 Diabetes Genetics Consortium. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57(4):1084-1092.
  22. Karges B, Prinz N, Placzek K, et al. A comparison of familial and sporadic type 1 diabetes among young patients. Diabetes Care. 2021;44(5):1116-1124.
  23. Richardson SJ, Morgan NG. Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. Curr Opin Pharmacol. 2018;43:11-19.
  24. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449-2462.
  25. Rewers R, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet. 2016;387(10035):2340-2348.
  26. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-2479.
  27. Ziegler AG, Kick K, Bonifacio E, et al; Fr1da Study Group. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA. 2020;323(4):339-351.
  28. Groβe J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of diabetic ketoacidosis of new-onset type 1 diabetes in children and adolescents in different countries correlates with human development index (HDI): an updated systematic review, meta-analysis, and meta-regression. Horm Metab Res. 2018;50(3):209-222.
  29. Barker JM, Goehrig SH, Barriga K, et al; DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-1404.
  30. Elding Larsson H, Vehik K, Bell R, et al; TEDDY Study Group; SEARCH Study Group; Swediabkids Study Group; DPV Study Group; Finnish Diabetes Registry Study Group. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347-2352.
  31. Elding Larsson H, Vehik K, Gesualdo P, et al; TEDDY Study Group. Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease. Pediatr Diabetes. 2014;15(2):118-126.
  32. Vehik K, Lynch KF, Schatz DA, et al; TEDDY Study Group. Reversion of b-cell autoimmunity changes risk of type 1 diabetes: TEDDY Study. Diabetes Care. 2016;39(9):1535-1542.
  33. Redondo MJ, Geyer S, Steck AK, et al; Type 1 Diabetes TrialNet Study Group. A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care. 2018;41(9):1887-1894.
  34. Sosenko JM, Krischer JP, Palmer JP, et al; Diabetes Prevention Trial–Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the Diabetes Prevention Trial–Type 1. Diabetes Care. 2008; 31(3):528-533.
  35. Sosenko JM, Skyler JS, Mahon J, et al; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study [published correction appears in Diabetes Care. 2018;41(4):913]. Diabetes Care. 2011;34(8):1785-1787.
  36. Type 1 diabetes (T1D) risk testing. https://t1d.medi-stats.com/landing?_ga=2.189642541.747135841.1620054096-1908955219.1608674064. Accessed May 3, 2021.
  37. TrialNet. Pathway to Prevention of T1D. ClinicalTrials.gov Identifier: NCT00097292. https://clinicaltrials.gov/ct2/show/NCT00097292. Updated February 6, 2020. Accessed December 20, 2020.
  38. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care. 2015;38(6):989-996.
  39. GlobalData Healthcare. FDA approval of Provention Bio’s teplizumab could bring the first disease-modifying therapy to the type 1 diabetes space. www.pharmaceutical-technology.com/comment/fda-approval-provention-bio-teplizumab-type-1-diabetes. Updated November 12, 2020. Accessed May 18, 2021.
  40. Herold KC, Bundy BN, Long SA, et al; Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-613.
  41. VanBuecken D, Lord S, Greenbaum CJ. Changing the course of disease in type 1 diabetes. In: Feingold KR, Anawalt B, Boyce A, et al, eds. Endotext. www.ncbi.nlm.nih.gov/books/NBK326738. Updated June 11, 2018. Accessed January 18, 2021.
  42. Sims EK, Geyer S, Bennett Johnson S, et al; Type 1 Diabetes TrialNet Study Group. Who is enrolling? The path to monitoring in type 1 diabetes: TrialNet’s Pathway to Prevention. Diabetes Care. 2019;42(12):2228-2236.
  43. Provention Bio Announces US FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals. Cision PRNewswire. January 4, 2021.
  44. TrialNet. Abatacept Prevention Study. www.trialnet.org/our-research/prevention-studies/abatacept. Accessed January 18, 2021.
  45. TrialNet. Hydroxychloroquine (HCQ). www.trialnet.org/our-research/prevention-studies/hydroxychloroquine-hcq. Accessed January 18, 2021.
  46. Sherry N, Hagopian W, Ludvigsson J, et al; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487-497.
  47. ClinicalTrials.gov. Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT). https://clinicaltrials.gov/ct2/show/NCT03875729. Updated October 19, 2020. Accessed January 18, 2021.
  48. TrialNet. Tolerance Using Plasmid (TOPPLE) Study: Phase 1. www.trialnet.org/our-research/newly-diagnosed-t1d/TOPPLE. Accessed May 18, 2021.
  49. CinicalTrials.gov. Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer). https://clinicaltrials.gov/ct2/show/NCT04233034. Accessed May 18, 2021